Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

dbSNP Short Genetic Variations

Welcome to the Reference SNP (rs) Report

All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs11554290

Current Build 157

Released September 3, 2024

Organism
Homo sapiens
Position
chr1:114713908 (GRCh38.p14) Help

The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.

Alleles
T>A / T>C / T>G
Variation Type
SNV Single Nucleotide Variation
Frequency
C=0.000 (0/478, ALFA)
C=0.000 (0/316, HapMap)
Clinical Significance
Reported in ClinVar
Gene : Consequence
NRAS : Missense Variant
Publications
46 citations
Genomic View
See rs on genome

ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.

Release Version: 20231103111315
Population Group Sample Size Ref Allele Alt Allele Ref HMOZ Alt HMOZ HTRZ HWEP
Total Global 478 T=1.000 C=0.000 1.0 0.0 0.0 N/A
European Sub 0 T=0 C=0 0 0 0 N/A
African Sub 426 T=1.000 C=0.000 1.0 0.0 0.0 N/A
African Others Sub 0 T=0 C=0 0 0 0 N/A
African American Sub 426 T=1.000 C=0.000 1.0 0.0 0.0 N/A
Asian Sub 0 T=0 C=0 0 0 0 N/A
East Asian Sub 0 T=0 C=0 0 0 0 N/A
Other Asian Sub 0 T=0 C=0 0 0 0 N/A
Latin American 1 Sub 0 T=0 C=0 0 0 0 N/A
Latin American 2 Sub 0 T=0 C=0 0 0 0 N/A
South Asian Sub 0 T=0 C=0 0 0 0 N/A
Other Sub 52 T=1.00 C=0.00 1.0 0.0 0.0 N/A


Help

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download
Study Population Group Sample Size Ref Allele Alt Allele
Allele Frequency Aggregator Total Global 478 T=1.000 C=0.000
Allele Frequency Aggregator African Sub 426 T=1.000 C=0.000
Allele Frequency Aggregator Other Sub 52 T=1.00 C=0.00
Allele Frequency Aggregator European Sub 0 T=0 C=0
Allele Frequency Aggregator Latin American 1 Sub 0 T=0 C=0
Allele Frequency Aggregator Latin American 2 Sub 0 T=0 C=0
Allele Frequency Aggregator South Asian Sub 0 T=0 C=0
Allele Frequency Aggregator Asian Sub 0 T=0 C=0
HapMap Global Study-wide 316 T=1.000 C=0.000
HapMap African Sub 116 T=1.000 C=0.000
HapMap American Sub 116 T=1.000 C=0.000
HapMap Asian Sub 84 T=1.00 C=0.00
Help

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements
Sequence name Change
GRCh38.p14 chr 1 NC_000001.11:g.114713908T>A
GRCh38.p14 chr 1 NC_000001.11:g.114713908T>C
GRCh38.p14 chr 1 NC_000001.11:g.114713908T>G
GRCh37.p13 chr 1 NC_000001.10:g.115256529T>A
GRCh37.p13 chr 1 NC_000001.10:g.115256529T>C
GRCh37.p13 chr 1 NC_000001.10:g.115256529T>G
NRAS RefSeqGene (LRG_92) NG_007572.1:g.7987A>T
NRAS RefSeqGene (LRG_92) NG_007572.1:g.7987A>G
NRAS RefSeqGene (LRG_92) NG_007572.1:g.7987A>C
Gene: NRAS, NRAS proto-oncogene, GTPase (minus strand)
Molecule type Change Amino acid[Codon] SO Term
NRAS transcript NM_002524.5:c.182A>T Q [CAA] > L [CTA] Coding Sequence Variant
GTPase NRas NP_002515.1:p.Gln61Leu Q (Gln) > L (Leu) Missense Variant
NRAS transcript NM_002524.5:c.182A>G Q [CAA] > R [CGA] Coding Sequence Variant
GTPase NRas NP_002515.1:p.Gln61Arg Q (Gln) > R (Arg) Missense Variant
NRAS transcript NM_002524.5:c.182A>C Q [CAA] > P [CCA] Coding Sequence Variant
GTPase NRas NP_002515.1:p.Gln61Pro Q (Gln) > P (Pro) Missense Variant
Help

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: A (allele ID: 362753 )
ClinVar Accession Disease Names Clinical Significance
RCV000418220.2 Malignant neoplasm of body of uterus Likely-Pathogenic
RCV000418396.2 Neoplasm of the large intestine Likely-Pathogenic
RCV000422640.2 Glioblastoma Likely-Pathogenic
RCV000423898.2 Hepatocellular carcinoma Likely-Pathogenic
RCV000424084.2 Acute myeloid leukemia Likely-Pathogenic
RCV000426122.2 Papillary renal cell carcinoma type 1 Likely-Pathogenic
RCV000428055.2 Multiple myeloma Likely-Pathogenic
RCV000429082.2 Ovarian serous cystadenocarcinoma Likely-Pathogenic
RCV000431333.2 Thyroid tumor Likely-Pathogenic
RCV000433349.2 Lung adenocarcinoma Likely-Pathogenic
RCV000433761.2 B-cell chronic lymphocytic leukemia Likely-Pathogenic
RCV000435412.2 Non-small cell lung carcinoma Pathogenic
RCV000435905.2 Malignant melanoma of skin Likely-Pathogenic
RCV000436539.2 Melanoma Pathogenic
RCV000438738.2 Transitional cell carcinoma of the bladder Likely-Pathogenic
RCV000441171.2 Neoplasm of brain Likely-Pathogenic
RCV000444188.2 Adrenal cortex carcinoma Likely-Pathogenic
RCV000444754.2 Nasopharyngeal neoplasm Likely-Pathogenic
RCV000444899.2 Gastric adenocarcinoma Likely-Pathogenic
RCV002524687.3 RASopathy Uncertain-Significance
Allele: C (allele ID: 28939 )
ClinVar Accession Disease Names Clinical Significance
RCV000014914.11 Thyroid cancer, nonmedullary, 2 Pathogenic
RCV000032847.11 Epidermal nevus Pathogenic
RCV000037574.9 Non-small cell lung carcinoma Pathogenic
RCV000114744.11 Large congenital melanocytic nevus Pathogenic
RCV000114745.10 Neurocutaneous melanocytosis Pathogenic
RCV000148032.7 Linear nevus sebaceous syndrome Pathogenic
RCV000413804.7 not provided Pathogenic
RCV000419710.4 Papillary renal cell carcinoma type 1 Likely-Pathogenic
RCV000420832.4 B-cell chronic lymphocytic leukemia Likely-Pathogenic
RCV000422078.4 Adrenal cortex carcinoma Likely-Pathogenic
RCV000422278.4 Ovarian serous cystadenocarcinoma Likely-Pathogenic
RCV000424455.4 Neoplasm of brain Likely-Pathogenic
RCV000424721.4 Lung adenocarcinoma Likely-Pathogenic
RCV000424960.4 Melanoma Pathogenic
RCV000430407.4 Malignant melanoma of skin Likely-Pathogenic
RCV000430593.4 Nasopharyngeal neoplasm Likely-Pathogenic
RCV000431883.4 Multiple myeloma Likely-Pathogenic
RCV000432961.4 Hepatocellular carcinoma Likely-Pathogenic
RCV000435687.4 Neoplasm of the large intestine Pathogenic
RCV000438052.4 Glioblastoma Likely-Pathogenic
RCV000439264.4 Gastric adenocarcinoma Likely-Pathogenic
RCV000440367.4 Transitional cell carcinoma of the bladder Likely-Pathogenic
RCV000441317.4 Acute myeloid leukemia Likely-Pathogenic
RCV000445249.4 Malignant neoplasm of body of uterus Likely-Pathogenic
RCV003992155.1 Noonan syndrome 6 Uncertain-Significance
Allele: G (allele ID: 263939 )
ClinVar Accession Disease Names Clinical Significance
RCV000291285.2 not provided Pathogenic
RCV000419053.2 Adrenal cortex carcinoma Likely-Pathogenic
RCV000419201.2 Multiple myeloma Likely-Pathogenic
RCV000420302.2 B-cell chronic lymphocytic leukemia Likely-Pathogenic
RCV000421291.2 Gastric adenocarcinoma Likely-Pathogenic
RCV000421496.2 Malignant neoplasm of body of uterus Likely-Pathogenic
RCV000426654.2 Nasopharyngeal neoplasm Likely-Pathogenic
RCV000427746.2 Malignant melanoma of skin Likely-Pathogenic
RCV000428903.2 Non-small cell lung carcinoma Likely-Pathogenic
RCV000430000.2 Neoplasm of the large intestine Likely-Pathogenic
RCV000431592.2 Melanoma Pathogenic
RCV000432170.2 Glioblastoma Likely-Pathogenic
RCV000434604.2 Neoplasm of brain Likely-Pathogenic
RCV000437312.2 Transitional cell carcinoma of the bladder Likely-Pathogenic
RCV000437545.2 Hepatocellular carcinoma Likely-Pathogenic
RCV000438468.2 Thyroid tumor Likely-Pathogenic
RCV000439526.2 Ovarian serous cystadenocarcinoma Likely-Pathogenic
RCV000439765.2 Lung adenocarcinoma Likely-Pathogenic
RCV000444278.2 Acute myeloid leukemia Likely-Pathogenic
RCV000444660.2 Papillary renal cell carcinoma type 1 Likely-Pathogenic
RCV003155143.2 Noonan syndrome 6 Likely-Pathogenic
Help

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement T= A C G
GRCh38.p14 chr 1 NC_000001.11:g.114713908= NC_000001.11:g.114713908T>A NC_000001.11:g.114713908T>C NC_000001.11:g.114713908T>G
GRCh37.p13 chr 1 NC_000001.10:g.115256529= NC_000001.10:g.115256529T>A NC_000001.10:g.115256529T>C NC_000001.10:g.115256529T>G
NRAS RefSeqGene (LRG_92) NG_007572.1:g.7987= NG_007572.1:g.7987A>T NG_007572.1:g.7987A>G NG_007572.1:g.7987A>C
NRAS transcript NM_002524.5:c.182= NM_002524.5:c.182A>T NM_002524.5:c.182A>G NM_002524.5:c.182A>C
NRAS transcript NM_002524.4:c.182= NM_002524.4:c.182A>T NM_002524.4:c.182A>G NM_002524.4:c.182A>C
GTPase NRas NP_002515.1:p.Gln61= NP_002515.1:p.Gln61Leu NP_002515.1:p.Gln61Arg NP_002515.1:p.Gln61Pro
Help

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

16 SubSNP, 2 Frequency, 66 ClinVar submissions
No Submitter Submission ID Date (Build)
1 CGAP-GAI ss16257702 Feb 28, 2004 (120)
2 OMICIA ss169655349 Aug 28, 2012 (137)
3 OMIM-CURATED-RECORDS ss256302353 Aug 26, 2010 (132)
4 DF-BWCC ss275515086 Nov 22, 2010 (133)
5 DF-BWCC ss275515087 Nov 22, 2010 (133)
6 DF-BWCC ss275515088 Nov 22, 2010 (133)
7 CLINVAR ss2136847189 Dec 04, 2016 (149)
8 ILLUMINA ss3725056885 Jul 12, 2019 (153)
9 CSS-BFX ss8442107639 Nov 02, 2024 (157)
10 CSS-BFX ss8442107640 Nov 02, 2024 (157)
11 CSS-BFX ss8442107641 Nov 02, 2024 (157)
12 EVA ss8935520539 Nov 02, 2024 (157)
13 EVA ss8979259739 Nov 02, 2024 (157)
14 EVA ss8981439893 Nov 02, 2024 (157)
15 LTPD ss8981611167 Nov 02, 2024 (157)
16 EVA ss8981702327 Nov 02, 2024 (157)
17 HapMap NC_000001.11 - 114713908 Apr 25, 2020 (154)
18 ALFA NC_000001.11 - 114713908 Nov 02, 2024 (157)
19 ClinVar RCV000014914.11 Nov 02, 2024 (157)
20 ClinVar RCV000032847.11 Nov 02, 2024 (157)
21 ClinVar RCV000037574.9 Nov 02, 2024 (157)
22 ClinVar RCV000114744.11 Nov 02, 2024 (157)
23 ClinVar RCV000114745.10 Nov 02, 2024 (157)
24 ClinVar RCV000148032.7 Nov 02, 2024 (157)
25 ClinVar RCV000291285.2 Nov 02, 2024 (157)
26 ClinVar RCV000413804.7 Nov 02, 2024 (157)
27 ClinVar RCV000418220.2 Nov 02, 2024 (157)
28 ClinVar RCV000418396.2 Nov 02, 2024 (157)
29 ClinVar RCV000419053.2 Nov 02, 2024 (157)
30 ClinVar RCV000419201.2 Nov 02, 2024 (157)
31 ClinVar RCV000419710.4 Nov 02, 2024 (157)
32 ClinVar RCV000420302.2 Nov 02, 2024 (157)
33 ClinVar RCV000420832.4 Nov 02, 2024 (157)
34 ClinVar RCV000421291.2 Nov 02, 2024 (157)
35 ClinVar RCV000421496.2 Nov 02, 2024 (157)
36 ClinVar RCV000422078.4 Nov 02, 2024 (157)
37 ClinVar RCV000422278.4 Nov 02, 2024 (157)
38 ClinVar RCV000422640.2 Nov 02, 2024 (157)
39 ClinVar RCV000423898.2 Nov 02, 2024 (157)
40 ClinVar RCV000424084.2 Nov 02, 2024 (157)
41 ClinVar RCV000424455.4 Nov 02, 2024 (157)
42 ClinVar RCV000424721.4 Nov 02, 2024 (157)
43 ClinVar RCV000424960.4 Nov 02, 2024 (157)
44 ClinVar RCV000426122.2 Nov 02, 2024 (157)
45 ClinVar RCV000426654.2 Nov 02, 2024 (157)
46 ClinVar RCV000427746.2 Nov 02, 2024 (157)
47 ClinVar RCV000428055.2 Nov 02, 2024 (157)
48 ClinVar RCV000428903.2 Nov 02, 2024 (157)
49 ClinVar RCV000429082.2 Nov 02, 2024 (157)
50 ClinVar RCV000430000.2 Nov 02, 2024 (157)
51 ClinVar RCV000430407.4 Nov 02, 2024 (157)
52 ClinVar RCV000430593.4 Nov 02, 2024 (157)
53 ClinVar RCV000431333.2 Nov 02, 2024 (157)
54 ClinVar RCV000431592.2 Nov 02, 2024 (157)
55 ClinVar RCV000431883.4 Nov 02, 2024 (157)
56 ClinVar RCV000432170.2 Nov 02, 2024 (157)
57 ClinVar RCV000432961.4 Nov 02, 2024 (157)
58 ClinVar RCV000433349.2 Nov 02, 2024 (157)
59 ClinVar RCV000433761.2 Nov 02, 2024 (157)
60 ClinVar RCV000434604.2 Nov 02, 2024 (157)
61 ClinVar RCV000435412.2 Nov 02, 2024 (157)
62 ClinVar RCV000435687.4 Nov 02, 2024 (157)
63 ClinVar RCV000435905.2 Nov 02, 2024 (157)
64 ClinVar RCV000436539.2 Nov 02, 2024 (157)
65 ClinVar RCV000437312.2 Nov 02, 2024 (157)
66 ClinVar RCV000437545.2 Nov 02, 2024 (157)
67 ClinVar RCV000438052.4 Nov 02, 2024 (157)
68 ClinVar RCV000438468.2 Nov 02, 2024 (157)
69 ClinVar RCV000438738.2 Nov 02, 2024 (157)
70 ClinVar RCV000439264.4 Nov 02, 2024 (157)
71 ClinVar RCV000439526.2 Nov 02, 2024 (157)
72 ClinVar RCV000439765.2 Nov 02, 2024 (157)
73 ClinVar RCV000440367.4 Nov 02, 2024 (157)
74 ClinVar RCV000441171.2 Nov 02, 2024 (157)
75 ClinVar RCV000441317.4 Nov 02, 2024 (157)
76 ClinVar RCV000444188.2 Nov 02, 2024 (157)
77 ClinVar RCV000444278.2 Nov 02, 2024 (157)
78 ClinVar RCV000444660.2 Nov 02, 2024 (157)
79 ClinVar RCV000444754.2 Nov 02, 2024 (157)
80 ClinVar RCV000444899.2 Nov 02, 2024 (157)
81 ClinVar RCV000445249.4 Nov 02, 2024 (157)
82 ClinVar RCV002524687.3 Nov 02, 2024 (157)
83 ClinVar RCV003155143.2 Nov 02, 2024 (157)
84 ClinVar RCV003992155.1 Nov 02, 2024 (157)
Help

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Added to this RefSNP Cluster:
Submission IDs Observation SPDI Canonical SPDI Source RSIDs
ss8442107639, ss8979259739, ss8981439893 NC_000001.10:115256528:T:A NC_000001.11:114713907:T:A (self)
RCV000418220.2, RCV000418396.2, RCV000422640.2, RCV000423898.2, RCV000424084.2, RCV000426122.2, RCV000428055.2, RCV000429082.2, RCV000431333.2, RCV000433349.2, RCV000433761.2, RCV000435412.2, RCV000435905.2, RCV000436539.2, RCV000438738.2, RCV000441171.2, RCV000444188.2, RCV000444754.2, RCV000444899.2, RCV002524687.3, ss275515086 NC_000001.11:114713907:T:A NC_000001.11:114713907:T:A (self)
ss8442107640, ss8935520539, ss8981611167, ss8981702327 NC_000001.10:115256528:T:C NC_000001.11:114713907:T:C (self)
RCV000014914.11, RCV000032847.11, RCV000037574.9, RCV000114744.11, RCV000114745.10, RCV000148032.7, RCV000413804.7, RCV000419710.4, RCV000420832.4, RCV000422078.4, RCV000422278.4, RCV000424455.4, RCV000424721.4, RCV000424960.4, RCV000430407.4, RCV000430593.4, RCV000431883.4, RCV000432961.4, RCV000435687.4, RCV000438052.4, RCV000439264.4, RCV000440367.4, RCV000441317.4, RCV000445249.4, RCV003992155.1, 159619, 7993568497, ss169655349, ss256302353, ss275515088, ss3725056885 NC_000001.11:114713907:T:C NC_000001.11:114713907:T:C (self)
ss16257702 NT_032977.9:85228446:T:C NC_000001.11:114713907:T:C (self)
ss8442107641, ss8935520539 NC_000001.10:115256528:T:G NC_000001.11:114713907:T:G (self)
RCV000291285.2, RCV000419053.2, RCV000419201.2, RCV000420302.2, RCV000421291.2, RCV000421496.2, RCV000426654.2, RCV000427746.2, RCV000428903.2, RCV000430000.2, RCV000431592.2, RCV000432170.2, RCV000434604.2, RCV000437312.2, RCV000437545.2, RCV000438468.2, RCV000439526.2, RCV000439765.2, RCV000444278.2, RCV000444660.2, RCV003155143.2, ss275515087, ss2136847189 NC_000001.11:114713907:T:G NC_000001.11:114713907:T:G (self)
Help

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

46 citations for rs11554290
PMID Title Author Year Journal
1654209 ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Mitsudomi T et al. 1991 Cancer research
2278970 RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. Vogelstein B et al. 1990 Genes, chromosomes & cancer
2674680 N-ras mutations in human cutaneous melanoma from sun-exposed body sites. van 't Veer LJ et al. 1989 Molecular and cellular biology
3122217 RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Janssen JW et al. 1987 Proceedings of the National Academy of Sciences of the United States of America
6587382 Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells. Yuasa Y et al. 1984 Proceedings of the National Academy of Sciences of the United States of America
8120410 Ras mutations in human melanoma: a marker of malignant progression. Ball NJ et al. 1994 The Journal of investigative dermatology
12460918 BRAF and RAS mutations in human lung cancer and melanoma. Brose MS et al. 2002 Cancer research
12727991 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Nikiforova MN et al. 2003 The Journal of clinical endocrinology and metabolism
14508525 BRAF mutations in papillary carcinomas of the thyroid. Fukushima T et al. 2003 Oncogene
16273091 BRAF mutation predicts sensitivity to MEK inhibition. Solit DB et al. 2006 Nature
16291983 Distinct sets of genetic alterations in melanoma. Curtin JA et al. 2005 The New England journal of medicine
16434492 Implications of NRAS mutations in AML: a study of 2502 patients. Bacher U et al. 2006 Blood
17699718 AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Davies BR et al. 2007 Molecular cancer therapeutics
18390968 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Adjei AA et al. 2008 Journal of clinical oncology
18633438 Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. Dessars B et al. 2009 The Journal of investigative dermatology
18948947 Somatic mutations affect key pathways in lung adenocarcinoma. Ding L et al. 2008 Nature
19075190 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Tyner JW et al. 2009 Blood
19880792 Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. Salerno P et al. 2010 The Journal of clinical endocrinology and metabolism
20130576 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G et al. 2010 Nature
20149136 PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Halaban R et al. 2010 Pigment cell & melanoma research
20179705 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI et al. 2010 Nature
20406486 Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. Søndergaard JN et al. 2010 Journal of translational medicine
20619739 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W et al. 2010 The Lancet. Oncology
20736745 NRAS mutations are rare in colorectal cancer. Irahara N et al. 2010 Diagnostic molecular pathology
21107323 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R et al. 2010 Nature
21305640 Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Vaughn CP et al. 2011 Genes, chromosomes & cancer
21576590 NRAS-mutant melanoma: response to chemotherapy. Soon CW et al. 2011 Archives of dermatology
21729679 Development of molecular biomarkers in individualized treatment of colorectal cancer. De Mattos-Arruda L et al. 2011 Clinical colorectal cancer
21829508 PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. Janku F et al. 2011 PloS one
22407852 RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. Sano H et al. 2012 International journal of hematology
22499344 Keratinocytic epidermal nevi are associated with mosaic RAS mutations. Hafner C et al. 2012 Journal of medical genetics
22761467 First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Martinez-Garcia M et al. 2012 Clinical cancer research
22773810 Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Ohashi K et al. 2012 Proceedings of the National Academy of Sciences of the United States of America
23392294 Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. Kinsler VA et al. 2013 The Journal of investigative dermatology
23414587 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Ascierto PA et al. 2013 The Lancet. Oncology
23515407 Characteristics of lung cancers harboring NRAS mutations. Ohashi K et al. 2013 Clinical cancer research
23538902 Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Haarberg HE et al. 2013 Molecular cancer therapeutics
23569304 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K et al. 2013 Journal of clinical oncology
23614898 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Morris EJ et al. 2013 Cancer discovery
24006476 Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Lim YH et al. 2014 Human molecular genetics
24033266 A systematic approach to assessing the clinical significance of genetic variants. Duzkale H et al. 2013 Clinical genetics
24370118 Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens. Bar J et al. 2014 Clinical lung cancer
25032700 NCI-60 whole exome sequencing and pharmacological CellMiner analyses. Reinhold WC et al. 2014 PloS one
25157968 Prospective enterprise-level molecular genotyping of a cohort of cancer patients. MacConaill LE et al. 2014 The Journal of molecular diagnostics
26619011 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Chang MT et al. 2016 Nature biotechnology
29525983 Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing. Lee JW et al. 2018 Journal of applied genetics
Help

The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.

Genome context:
Select flank length:

Genomic regions, transcripts, and products
Top Help

NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Software version is: 2.0.1.post825+45319f0